StockNews.com upgraded shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) from a sell rating to a hold rating in a report published on Tuesday. Separately, HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, April 9th. Get Our Latest Stock Analysis […]